demonstrated that long-term clinical responses appear in patients with melanoma, renal cell cancer, and nonsmall cell lung cancer while anti-PD-1- and anti-PD-L1-directed therapies were conducted (30). This evidence concerns the gene PDCD1 and lung cancer.